Eris Lifesciences Limited has informed the Exchange regarding 'Credit Rating of Eris Therapeutics Limited'.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
India Ratings and Research (Ind-Ra) has assigned IND AA/Stable/IND A1+ rating to INR 1,000 million bank loan facilities of Eris Therapeutics Limited (ETL) and affirmed the same rating on INR 4,200 million facilities (reduced from INR 4,686 million) of the wholly owned subsidiary. The stable outlook reflects sustained healthy operating performance with EBITDA of INR 8.5 billion in 9MFY26, improved net leverage to 2.2x in FY25 from 3.9x in FY24, and strong strategic linkages with parent Eris Lifesciences. The rating history shows ETL's rating was upgraded from IND AA- to IND AA in May 2025. ETL's standalone FY25 performance showed revenue of INR 7,589 million, EBITDA margin of 52%, interest coverage of 12.0x, and net leverage of 0.8x.
The affirmation of AA rating with stable outlook is positive for Eris Lifesciences shareholders, indicating strong creditworthiness of its subsidiary and supporting the company's ability to service debt from acquisitions. The reduced facility size suggests scheduled debt repayments are on track.